DULUTH, Ga. (JANUARY 25, 2024) — Boehringer Ingelheim announced today the launch of Vaxxilive® Cocci 3, a poultry coccidiosis vaccine previously known as Hatchpak® Cocci III. 

VAXXILIVE COCCI 3 is a tool for the prevention of coccidiosis and a biological alternative to in-feed anticoccidial drugs. The vaccine works to stimulate the bird’s natural immune response while minimizing tissue damage. In short: VAXXILIVE COCCI 3 is tough on coccidiosis and gentle on birds. 

The vaccine contains the same proven formula producers have come to rely on, including three genetically stable precocious strains of the important Eimeria species that affects broilers. With shortened life cycles, precocious strains can achieve immunity earlier than non-precocious strains.¹⁻³

Because the precocious strains have a faster turnover rate, VAXXILIVE COCCI 3 triggers less oocyst production and less tissue damage.¹⁻³ The vaccine ultimately achieves better immunity while preserving barrier integrity and producing minimal vaccine reactions.² In addition, the vaccine can be used year-round, enabling better management of coccidiosis with less likelihood of developing chemical resistance than protocols that rotate between vaccination, chemical treatment and feed additives. 

Boehringer has also used this launch as an opportunity for process innovation, drastically improving procedures to enable more consistent, quality manufacturing.  

“As with any vaccination, choosing a product is only half the battle,” said Rick Phillips, DVM, Director, Key Account Veterinarians, Boehringer Ingelheim Poultry. “Our experienced and knowledgeable field team provides industry-leading support to producers, regularly visiting them to review vaccination protocols, and create and maintain comprehensive poultry health programs.” 

VAXXILIVE COCCI 3 is now widely available. Ask your flock veterinarian or a Boehringer Ingelheim representative for more information.  

To learn more about Boehringer Ingelheim Animal Health and the services available to producers and veterinarians, visit https://bi-animalhealth.com/. 

  

References:  

1 Boehringer Ingelheim Study 1009. Data on file at Boehringer Ingelheim. 

2 Boehringer Ingelheim Study 0210. Data on file at Boehringer Ingelheim. 

3 Boehringer Ingelheim Study 0410. Data on file at Boehringer Ingelheim. 

 

*** 

 

About Boehringer Ingelheim Animal Health USA 

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. 

As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. 

Boehringer Ingelheim Animal Health has deep roots in the U.S. From a start in St. Joseph, Missouri, more than 100 years ago, it has grown to encompass seven sites. Boehringer Ingelheim Animal Health’s portfolio contains widely used and well-respected vaccines, parasite-control products and therapeutics for pets, horses and livestock. 

VAXXILIVE® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. HATCHPAK® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-POU-0060-2023